Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Effect of cabozantinib on transcriptome and signaling pathways in leukemic cell line Kasumi-1

ABSTRACT: Effect of cabozantinib on transcriptome and signaling pathways in leukemic cell line Kasumi-1

PROVIDER: PRJNA644355 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR12153147_1.fastq.gz	Fastqsanger.gz
	SRR12153147_2.fastq.gz	Fastqsanger.gz
	SRR12153148_1.fastq.gz	Fastqsanger.gz
	SRR12153148_2.fastq.gz	Fastqsanger.gz
	SRR12153149_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 8

Similar Datasets

Effect of cabozantinib on transcriptome and signaling pathways in leukemic cell line Kasumi-1

Project description:To identify molecular effects of the tyrosine kinase inhibitor cabozantinib (XL184), we applied gene expression profiling on human acute leukemic cell lines Kasumi-1, which harbors t(8;21) coupled with KIT mutation, by Whole Transcriptome Shotgun Sequencing (RNA-seq). After Kasumi-1 cells were treated with 100nM cabozantinib for 4h or 24h, differentially expressed genes (DEGs) of 124 genes upregulated and 416 were downregulated in 4h, and 184 genes upregulated and 69 genes were downregulated in 24h treatment, compared with vehicle group.

2021-04-22 | GSE153853 | GEO

Effect of caboznatinib on transcriptome and signaling pathways in leukemic cell line K562

Project description:To identify molecular effects of the tyrosine kinase inhibitor cabozantinib (XL184), we applied gene expression profiling in human erythroid leukemic cell lines K562 using Whole Transcriptome Shotgun Sequencing (RNA-seq). After K562 cell were treated with 1uM cabozantinib for 48 h, differentially expressed genes (DEGs) of 241 genes upregulated and 569 were downregulated were found compared with vehicle group. Up-regulated genes enriched in erythroid maturation associated pathways, such as heme metabolism, transcription factor GATA1 targets, and globin synthesis, while those genes downregulated after expose to cabozantinib were enriched in pathways involved in cell proliferation and cell survival function.

2021-05-21 | GSE151003 | GEO

Transcriptomic differences in cabozantinib-resisant AML cells.

Project description:Cabozantinib is a type II tyrosine kinase inhibitor (TKI), which is approved by FDA for treating several solid tumors including advanced/progressive metastatic medullar thyroid cancer, advanced renal cell carcinoma, and advanced and progressive hepatocellular carcinoma. Moreover, we and others revealed its cytotoxicity on FLT3-ITD, KIT-driven t(8;21) AML cells, and its efficacy on promoting erythroid differentiation of leukemic cell line K562. A clinical trial report also suggested that cabozantinib is well tolerated in FLT3-ITD AML patients. While those findings highlighted the feasibility of cabozantinib targeting specific AML subtypes, it is unclear whether cabozantinib treatment arises resistance in cancer cells. To identify the mechanism and transcriptomic change of cabozantinib resistance, we established drug-resistant cell lines by culturing Molm13 and MV4-11 leukemic cell lines in increasing drug concentrations.

2026-02-25 | GSE234724 | GEO

CUT-TAG for Kasumi-1 cell line

Project description:Next-generation sequencing (NGS) has revolutionized systems-based analysis of cellular pathways. The goals of this study are to explore CUT-TAG results in Kasumi-1 cell line.

2026-03-13 | GSE286879 | GEO

RNA-seq for Kasumi-1 cell line in either the absence or presence of ANP32B

Project description:Purpose: Next-generation sequencing (NGS) has revolutionized systems-based analysis of cellular pathways. The goals of this study are to compare RNA-seq results for Kasumi-1 cell line in either the absence or presence of ANP32B

2023-09-12 | GSE242848 | GEO

CUT-TAG for Kasumi-1 cell line

Project description:CUT-TAG for Kasumi-1 cell line

| PRJNA1210482 | ENA

Differential cytogenomics and miRNA signature of the Acute Myeloid Leukemia Kasumi-1 cell line CD34+38- compartment

Project description:The t(8;21) Acute Myeloid Leukaemia (AML) Kasumi-1cell line with N822K KIT mutation, is a model system for leukemogenesis. As AML initiating cells reside in the CD34+CD38– fraction, we addressed the refined cytogenomic characterization and miRNA expression of Kasumi-1 cell line and its FACS-sorted subpopulations focussing on this compartment. By conventional cytogenetics, Spectral Karyotyping and array-CGH the cytogenomic profile of Kasumi-1 cells evidenced only subtle regions differentially represented in CD34+CD38– cells.

2010-02-11 | GSE20239 | GEO

GATA-2 occupancy in Kasumi-3 cell line

Project description:GATA-2 is a master regulator of hematopoiesis which controls expression of multiple genes and is implicated in acute myeloid leukemia (AML). However, the molecular mechanism how GATA-2 deregulation causes leukemogenesis is still unclear. In this study, GATA-2 ChIP-squ analysis was conducted in Kasumi-3 AML cell line to identify GATA-2 target genes which play important roles in the pathogenesis of AML. ChIP with GATA-2 antibody was conducted in Kasumi-3 AML cell line and ChIP-seq profile was generated by deep sequencing.

2016-08-05 | E-GEOD-84782 | biostudies-arrayexpress

Effect of caboznatinib on transcriptome and signaling pathways in leukemic cell line K562

Project description:Effect of caboznatinib on transcriptome and signaling pathways in leukemic cell line K562

| PRJNA634358 | ENA

GATA-2 occupancy in Kasumi-3 cell line

2016-08-05 | GSE84782 | GEO